Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2026LymphaticsOpen Access

Cytoreduction-Adapted Outpatient Venetoclax Ramp-Up in CLL/SLL: A Real-World Pilot Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMonica WallinTRTeshmanie RampersaudSKSally Ko

Discussion

Loading...

Member takes

Overview

Pilot study demonstrates early safety of outpatient venetoclax ramp-up in patients with CLL/SLL, suggesting practical feasibility.

Key Points

  • This study aims to evaluate the feasibility and safety of a cytoreduction-adapted outpatient venetoclax ramp-up in patients with CLL/SLL.
  • Single-center, IRB-approved retrospective pilot study of 30 patients with CLL/SLL.
  • All patients received cytoreductive therapy and met low-tumor-burden criteria before venetoclax initiation.
  • Venetoclax was self-administered at home with minimal laboratory monitoring (only one assessment per week).
  • No instances of laboratory or clinical tumor lysis syndrome occurred during the ramp-up.
  • Monitoring compliance was 100% with no hospitalizations, IV hydration, or treatment discontinuations.
  • Pilot data support the feasibility of outpatient venetoclax initiation in adequately cytoreduced patients.

Cite This Study

Wallin et al. (2026) studied this question.

synapsesocial.com/papers/6a6d985be258b358b3c6b974https://doi.org/10.3390/lymphatics4030040
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia2015 · 1,935 citations
  2. 2Tumour lysis syndrome: new therapeutic strategies and classification2004 · 1,079 citations
  3. 3Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax2024 · 11 citations
  4. 4First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia2023 · 309 citations
  5. 5Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables2019 · 177 citations